Role of BNP levels on the prognosis of decompensated advanced heart failure

Arquivos Brasileiros de Cardiologia

Volumn 100, Issue 3, 2013, Pages 281-287

  Pereira Barretto, Antônio Carlos ^a   Del Carlo, Carlos Henrique ^a   Cardoso, Juliano Novaes ^a   Ochiai, Marcelo Eid ^a   Lima, Marcelo Villaça ^a   Curiati, Milena Cardoso ^a   Scipioni, Airton Roberto ^a   Ramires, José Antônio Franchini ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Heart Failure; Natriuretic Peptides; Prognosis; Survivorship (Public Health)

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; UREA; VASOACTIVE AGENT;

ADULT; AGED; ARTICLE; CHAGAS DISEASE; CINEANGIOCARDIOGRAPHY; DEATH; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEROLOGY; SYSTOLIC DYSFUNCTION;

EID: 84876576233     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.5935/abc.20130066     Document Type: Article

References (14)

1. Pereira-Barretto AC, Del Carlo CH, Cardoso JN, Morgado PC, Munhoz RT, Eid MO, et al. Re-hospitalizações e morte por insuficiência cardíaca: índices ainda alarmantes. Arq Bras Cardiol. 2008;91(5):335-41.
2. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, et al; CHARM investigators. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65-75.
3. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-7.
4. Mueller C, Scholer H, Laile-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350(7):647-54.
5. Verdiani V, Nozzoli C, Bacci F, Cecchin A, Rutili MS, Palodini S, et al. Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. Eur J Heart Fail. 2005;7(4):566-71.
6. Bettencourt P, Ferreira S, Azevedo A, Ferreira A. Preliminary data on the potential usefulness of B-type natriuretic peptide outcome after hospital discharge in patients with heart failure. Am J Med. 2002;113(3):215-9.
7. Bocchi EA, Marcondes-Braga FG, Ayub-Ferreira SM, Rohde LE, Oliveira WA, Almeida DR, et al.; Sociedade Brasileira de Cardiologia. III Diretriz brasileira de insuficiência cardíaca crônica. Arq Bras Cardiol. 2009;93(1 supl.1):1-71.
8. Krum H, Teerlink JR. Medical therapy for chronic heart failure. Lancet. 2011;378(9792):713-21.
9. Gislason GH, Rasmussen JN, Abuldstrom SZ, Schramm TK, Hansen ML, Bush P, et al. Persistent use of evidence based pharmacotherapy in heart failure is associated with improve outcomes. Circulation. 2007;116(7):737-44.
10. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al; Val-HeFT investigators. Changes in brain natriuretic peptide and norepinephrine overtime and mortality and morbidity in the Valsartan Heart Failure Trial(Val-HeFT). Circulation. 2003;107(9):1278-83.
11. Fonarow GC, Pocock WF, Korwich TB, Phillips CO, Givertz MM, Lapatin M, et al; ADHERE Scientific Advisory Committee and Investigators. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in hospital mortality from ADHERE. Am J Cardiol. 2008;101(2):231-7.
12. Lanfear DE, Peterson EL, Campbell J, Phatak H, Wu D, Wells K, et al. Relation of worsened renal function during hospitalization for heart failure to long-term outcomes and re-hospitalization. Am J Cardiol. 2011;107(1):74-8.
13. Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ. Risk stratification in a Brazilian hospital based cohort of 1220 outpatients with heart failure: role of Chagas' disease. Int J Cardiol. 2005;102(2):239-47.
14. Silva CP, Del Carlo CH, Oliveira Junior MT, Scipioni A, Strunz-Cassaro C, Ramires JA, et al. Porque os portadores de cardiomiopatia chagásica têm pior evolução que os não chagásicos? Arq Bras Cardiol. 2008;91(6):358-62.